Delivery Order SPE2DB24D2012-SPE2DB25FBWAC

Award Date 5/15/25
Potential Completion Date 5/16/25
Potential Value $4.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,678.35, is for the delivery of 4,567,859,053 units of the medication XELJANZ XR 11 MG TABLET. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,084.42, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a prescription medication. The contract has a period of performance through April 17, 2025 and is a firm fixed-price, non-set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,621.77, is for the provision of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract has a period of performance through July 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This is a $7,837.41 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of XELJANZ XR 11 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of May 28, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the delivery of XELJANZ XR 11 MG TABLET, a pharmaceutical product, with a potential value of $2,393.39 and a completion date of February 8, 2024. This delivery order is part of a larger indefinite...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XELJANZ XR 11 MG TABLET. The contract has a firm fixed price of $30,050.50 and a completion date of January 17, 2025. The contract was not set aside for any specific business type. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a $9,937.42 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, with a performance period through April 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $35,395.89, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S and has an ultimate completion date of April 1, 2025. The contract is a firm-fixed-price type and was not set aside for any specific business category. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product, with a ceiling value of $3,118.90 and a performance period ending on May 15, 2025. The contract is a Firm Fixed Price, non-set-aside award. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,757.10, is for the delivery of XELJANZ XR 11 MG TABLET UU 30S, a pharmaceutical product. The contract is a firm fixed price delivery order, with a period of performance through May 12, 2025. This contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a...
  • SPE2DB24D2012
    Indefinite Delivery Contract
  • SPE2DB24D2012-SPE2DB25FBWAC
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,527.97, is for the delivery of XELJANZ XR 11 MG TABLET. The contract has an ultimate completion date of May 16, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle through December 2026. This delivery order is not designated as a set-aside contract.

Generated 8/14/25, 10:05 AM